BRIEF-Eliem Therapeutics Announces Agreement To Acquire Tenet Medicines And Concurrent $120 Mln Private Placement

Reuters04-11

April 11 (Reuters) - Eliem Therapeutics Inc :

* ELIEM THERAPEUTICS ANNOUNCES AGREEMENT TO ACQUIRE TENET MEDICINES AND CONCURRENT $120 MILLION PRIVATE PLACEMENT

* ELIEM THERAPEUTICS INC - COMBINED COMPANY EXPECTED TO HAVE APPROXIMATELY $210 MILLION OF CASH AND CASH EQUIVALENTS

* ELIEM THERAPEUTICS INC - COMBINED COMPANY PLANS TO FOCUS ON ADVANCING TNT119

* ELIEM THERAPEUTICS INC - TENET STOCKHOLDERS ARE ENTITLED TO RECEIVE SHARES OF ELIEM'S COMMON STOCK UPON CLOSING OF ACQUISITION

* ELIEM THERAPEUTICS INC - TENET STOCKHOLDERS ARE ENTITLED TO RECEIVE SHARES OF ELIEM'S COMMON STOCK UPON CLOSING OF ACQUISITION

* ELIEM THERAPEUTICS INC - PRE-ACQUISITION TENET EQUITYHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 15% OF COMBINED COMPANY

* ELIEM THERAPEUTICS INC - AND PRE-ACQUISITION ELIEM EQUITYHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 85% OF COMBINED COMPANY

* ELIEM THERAPEUTICS INC - ACQUISITION AGREEMENT HAS BEEN UNANIMOUSLY APPROVED BY BOARDS OF DIRECTORS OF BOTH COMPANIES

* ELIEM THERAPEUTICS INC - IN PRIVATE PLACEMENT, ELIEM HAS AGREED TO SELL 31,238,282 SHARES OF ITS COMMON STOCK AT A PRICE OF $3.84 PER SHARE

* ELIEM THERAPEUTICS- COMBINED CO TO INITIATE PHASE 2 TRIALS OF TNT119 FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS AND IMMUNE THROMBOCYTOPENIA IN H2 2024

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2426258637?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-11 19:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2426258637","market":"us","top_or_hot":-1,"title":"BRIEF-Eliem Therapeutics Announces Agreement To Acquire Tenet Medicines And Concurrent $120 Mln Private Placement","media":"Reuters","content":"<html><body><p>April 11 (Reuters) - <a href=\"https://laohu8.com/S/ELYM\">Eliem Therapeutics</a> Inc   :</p><p>   * ELIEM THERAPEUTICS ANNOUNCES AGREEMENT TO ACQUIRE TENET MEDICINES AND CONCURRENT $120 MILLION PRIVATE PLACEMENT</p><p>   * ELIEM THERAPEUTICS INC - COMBINED COMPANY EXPECTED TO HAVE APPROXIMATELY $210 MILLION OF CASH AND CASH EQUIVALENTS</p><p>   * ELIEM THERAPEUTICS INC - COMBINED COMPANY PLANS TO FOCUS ON ADVANCING TNT119</p><p>   * ELIEM THERAPEUTICS INC - TENET STOCKHOLDERS ARE ENTITLED TO RECEIVE SHARES OF ELIEM'S COMMON STOCK UPON CLOSING OF ACQUISITION</p><p>   * ELIEM THERAPEUTICS INC - TENET STOCKHOLDERS ARE ENTITLED TO RECEIVE SHARES OF ELIEM'S COMMON STOCK UPON CLOSING OF ACQUISITION</p><p>   * ELIEM THERAPEUTICS INC - PRE-ACQUISITION TENET EQUITYHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 15% OF COMBINED COMPANY</p><p>   * ELIEM THERAPEUTICS INC - AND PRE-ACQUISITION ELIEM EQUITYHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 85% OF COMBINED COMPANY</p><p>   * ELIEM THERAPEUTICS INC - ACQUISITION AGREEMENT HAS BEEN UNANIMOUSLY APPROVED BY BOARDS OF DIRECTORS OF BOTH COMPANIES</p><p>   * ELIEM THERAPEUTICS INC - IN PRIVATE PLACEMENT, ELIEM HAS AGREED TO SELL 31,238,282 SHARES OF ITS COMMON STOCK AT A PRICE OF $3.84 PER SHARE</p><p>   * ELIEM THERAPEUTICS- COMBINED CO TO INITIATE PHASE 2 TRIALS OF TNT119 FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS AND IMMUNE THROMBOCYTOPENIA IN H2 2024</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Eliem Therapeutics Announces Agreement To Acquire Tenet Medicines And Concurrent $120 Mln Private Placement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Eliem Therapeutics Announces Agreement To Acquire Tenet Medicines And Concurrent $120 Mln Private Placement\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-11 19:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>April 11 (Reuters) - Eliem Therapeutics Inc   :   * ELIEM THERAPEUTICS ANNOUNCES AGREEMENT TO ACQUIRE TENET MEDICINES AND CONCURRENT $120 MILLION PRIVATE PLACEMENT   * ELIEM THERAPEUTICS INC - ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDCO","symbol_name":"麦迪逊医药","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2426258637","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2426258637","pubTimestamp":1712834504,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"April 11 (Reuters) - Eliem Therapeutics Inc   :   * ELIEM THERAPEUTICS ANNOUNCES AGREEMENT TO ACQUIRE TENET MEDICINES AND CONCURRENT $120 MILLION PRIVATE PLACEMENT   * ELIEM THERAPEUTICS INC - COMBINE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDCO":"麦迪逊医药","BK4139":"生物科技","BK4539":"次新股","ELYM":"Eliem Therapeutics"},"translate_title":"简报——Eliem Therapeutics宣布同意收购Tenet Medicines并同时进行1.2亿美元的私募","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELYM":1,"MDCO":1},"content_text":"April 11 (Reuters) - Eliem Therapeutics Inc   :   * ELIEM THERAPEUTICS ANNOUNCES AGREEMENT TO ACQUIRE TENET MEDICINES AND CONCURRENT $120 MILLION PRIVATE PLACEMENT   * ELIEM THERAPEUTICS INC - COMBINED COMPANY EXPECTED TO HAVE APPROXIMATELY $210 MILLION OF CASH AND CASH EQUIVALENTS   * ELIEM THERAPEUTICS INC - COMBINED COMPANY PLANS TO FOCUS ON ADVANCING TNT119   * ELIEM THERAPEUTICS INC - TENET STOCKHOLDERS ARE ENTITLED TO RECEIVE SHARES OF ELIEM'S COMMON STOCK UPON CLOSING OF ACQUISITION   * ELIEM THERAPEUTICS INC - TENET STOCKHOLDERS ARE ENTITLED TO RECEIVE SHARES OF ELIEM'S COMMON STOCK UPON CLOSING OF ACQUISITION   * ELIEM THERAPEUTICS INC - PRE-ACQUISITION TENET EQUITYHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 15% OF COMBINED COMPANY   * ELIEM THERAPEUTICS INC - AND PRE-ACQUISITION ELIEM EQUITYHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 85% OF COMBINED COMPANY   * ELIEM THERAPEUTICS INC - ACQUISITION AGREEMENT HAS BEEN UNANIMOUSLY APPROVED BY BOARDS OF DIRECTORS OF BOTH COMPANIES   * ELIEM THERAPEUTICS INC - IN PRIVATE PLACEMENT, ELIEM HAS AGREED TO SELL 31,238,282 SHARES OF ITS COMMON STOCK AT A PRICE OF $3.84 PER SHARE   * ELIEM THERAPEUTICS- COMBINED CO TO INITIATE PHASE 2 TRIALS OF TNT119 FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS AND IMMUNE THROMBOCYTOPENIA IN H2 2024Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2426258637"}